Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03430934 · ClinicalTrials.gov registry record · Early Phase 1
Non-invasive Fluorescent Imaging System for Imaging Mohs Tumor
A Early Phase 1 study, sponsored by University of Missouri-Columbia.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 11
- Enrollment target
NCT03430934 is a Early Phase 1 study that has completed, run by University of Missouri-Columbia. The registered enrollment target is 11 participants.
The verdict
NCT03430934, a Early Phase 1 study, has completed, sponsored by University of Missouri-Columbia.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
The objective of this study is to correlate traditional histological Mohs tissue mapping of a cutaneous tumor with the ICG-mapping procedure. The use of intradermal ICG in a cutaneous tumor during MMS followed by visualization using a fluorescent imaging system could allow surgeons to directly visualize, and roughly map the extent of a primary skin cancer and plan the Mohs procedure (i.e. the initial excision size and subsequent layer widths) accordingly.
Interventions
- COMBINATION_PRODUCT NAVI mapping with Indocyanine green
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2018-07-01 |
| Est. Completion | 2019-08-01 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03430934
The ClinicalTrials.gov registry entry for NCT03430934 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Missouri-Columbia, which has 291 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which NAVI mapping with Indocyanine green is the first listed.
NCT03430934 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03430934 about?
NCT03430934 is a clinical study titled "Non-invasive Fluorescent Imaging System for Imaging Mohs Tumor". The objective of this study is to correlate traditional histological Mohs tissue mapping of a cutaneous tumor with the ICG-mapping procedure. The use of intradermal ICG in a cutaneous tumor during MMS followed by visualization using a fluorescent imaging system could allow surgeons to directly visua...
What is the current status of trial NCT03430934?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 11 participants. The study started on 2018-07-01. Estimated completion is 2019-08-01.
What interventions are being tested in trial NCT03430934?
The interventions under investigation include: NAVI mapping with Indocyanine green (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT03430934?
This trial is sponsored by University of Missouri-Columbia, which has 291 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.